American Journal of Kidney Diseases
Volume 48, Issue 3 , Pages 464-472, September 2006

A Randomized, Multicenter, Open-Label Trial to Determine Peritonitis Rate, Product Defect, and Technique Survival Between ANDY-Disc® and UltraBag® in Patients on CAPD

Department of Nephrology, Institute of Urology and Nephrology; Clinical Research Centre; and Department of Paediatrics, Institute of Paediatrics, Kuala Lumpur Hospital; Departments of Medicine and Paediatrics, Penang Hospital; Departments of Medicine and Paediatrics, Sultanah Aminah Hospital, Johor Bahru; Departments of Medicine and Paediatrics, Seremban Hospital; and Department of Nephrology, Selayang Hospital, Malaysia.

Received 28 November 2005; accepted 9 May 2006. published online 27 July 2006.

Background: With the various twin-bag systems available on the market, we decided to conduct a therapeutic equivalence study comparing ANDY-Disc (Fresenius Medical Care, Bad Homburg, Germany) with UltraBag (Baxter, Deerfield, IL) in patients on continuous ambulatory peritoneal dialysis (CAPD) therapy. Methods: This multicenter, open-label, parallel-group, randomized trial is designed to show the therapeutic equivalence of ANDY-Disc with UltraBag. All CAPD patients from the 6 participating centers who met inclusion/exclusion criteria were enrolled into the trial. They were randomly assigned and converted from the Y-disconnect system (Ultraset; Baxter) to the twin-bag systems. The primary outcome variable is peritonitis, and secondary outcome parameters are technique failure or product defect. Results: From April 2002 to May 2003, a total of 270 patients were recruited for this study. Overall peritonitis rates were 22.9 patient-months/episode for ANDY-Disc and 35.0 patient-months/episode for UltraBag. The overall peritonitis rate for ANDY-Disc was 53% greater compared with UltraBag, but the 95% confidence interval overlaps the prespecified margin of equivalence. There were more product defects reported with ANDY-Disc; 236 product defects compared with 17 with UltraBag. The time series of the number of product defects and peritonitis count on the ANDY-Disc arm suggests a possible cause-and-effect relationship. Conclusion: Therapeutic equivalence of ANDY-Disc to UltraBag could not be established with respect to peritonitis. There is a trend toward greater risk for peritonitis on the Andy-Disc arm. There also is a suggestive cause-and-effect relation between the occurrence of product defect and peritonitis on the ANDY-Disc arm during the early part of the trial.

Index Words:  Continuous ambulatory peritoneal dialysis (CAPD) , peritonitis , ANDY-Disc , UltraBag , twin-bag system

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Originally published online as doi:10.1053/j.ajkd.2006.05.008 on July 26, 2006.Support: Supported in part by grants from Fresenius Medical Care and Baxter. Potential conflicts of interest: None.

PII: S0272-6386(06)00840-7

doi:10.1053/j.ajkd.2006.05.008

American Journal of Kidney Diseases
Volume 48, Issue 3 , Pages 464-472, September 2006